214 related articles for article (PubMed ID: 35739003)
1. Omega-3-fatty acids: Do they prevent cardiovascular disease?
Mason RP; Sherratt SCR; Eckel RH
Best Pract Res Clin Endocrinol Metab; 2023 May; 37(3):101681. PubMed ID: 35739003
[TBL] [Abstract][Full Text] [Related]
2. Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues.
Sherratt SCR; Libby P; Budoff MJ; Bhatt DL; Mason RP
Curr Atheroscler Rep; 2023 Jan; 25(1):1-17. PubMed ID: 36580204
[TBL] [Abstract][Full Text] [Related]
3. Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements.
Miller M; Tokgozoglu L; Parhofer KG; Handelsman Y; Leiter LA; Landmesser U; Brinton EA; Catapano AL
Expert Rev Cardiovasc Ther; 2022 Aug; 20(8):609-625. PubMed ID: 35876118
[TBL] [Abstract][Full Text] [Related]
4. New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease.
Preston Mason R
Curr Atheroscler Rep; 2019 Jan; 21(1):2. PubMed ID: 30637567
[TBL] [Abstract][Full Text] [Related]
5. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid.
Chapman MJ; Zamorano JL; Parhofer KG
Pharmacol Ther; 2022 Sep; 237():108172. PubMed ID: 35304222
[TBL] [Abstract][Full Text] [Related]
6. Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides.
Kedia AW; Lynch E
Postgrad Med; 2015; 127(8):869-73. PubMed ID: 26453247
[TBL] [Abstract][Full Text] [Related]
7. TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
Handelsman Y; Shapiro MD
Endocr Pract; 2017 Jan; 23(1):100-112. PubMed ID: 27819772
[TBL] [Abstract][Full Text] [Related]
8. The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention.
Trivedi K; Le V; Nelson JR
Postgrad Med; 2021 Jan; 133(1):28-41. PubMed ID: 32762268
[TBL] [Abstract][Full Text] [Related]
9. Omega n-3 Supplementation: Exploring the Cardiovascular Benefits Beyond Lipoprotein Reduction.
Zambon A; Pirillo A; Zambon S; Norata GD; Catapano AL
Curr Atheroscler Rep; 2020 Oct; 22(12):74. PubMed ID: 33009961
[TBL] [Abstract][Full Text] [Related]
10. Eicosapentaenoic Acid Versus Docosahexaenoic Acid as Options for Vascular Risk Prevention: A Fish Story.
Singh S; Arora RR; Singh M; Khosla S
Am J Ther; 2016; 23(3):e905-10. PubMed ID: 25828517
[TBL] [Abstract][Full Text] [Related]
11. Icosapent ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol.
Bazarbashi N; Miller M
Expert Rev Cardiovasc Ther; 2020 Apr; 18(4):175-180. PubMed ID: 32228246
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular Disease Risk Reduction in Mild-Moderate Hypertriglyceridemia: Integrating Prescription of Omega-3 with Standard Treatment.
Picard F; Steg PG
Curr Atheroscler Rep; 2021 Mar; 23(6):27. PubMed ID: 33788024
[TBL] [Abstract][Full Text] [Related]
13. Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options.
Weintraub H
Atherosclerosis; 2013 Oct; 230(2):381-9. PubMed ID: 24075771
[TBL] [Abstract][Full Text] [Related]
14. Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association.
Skulas-Ray AC; Wilson PWF; Harris WS; Brinton EA; Kris-Etherton PM; Richter CK; Jacobson TA; Engler MB; Miller M; Robinson JG; Blum CB; Rodriguez-Leyva D; de Ferranti SD; Welty FK;
Circulation; 2019 Sep; 140(12):e673-e691. PubMed ID: 31422671
[TBL] [Abstract][Full Text] [Related]
15. The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia.
Backes J; Anzalone D; Hilleman D; Catini J
Lipids Health Dis; 2016 Jul; 15(1):118. PubMed ID: 27444154
[TBL] [Abstract][Full Text] [Related]
16. Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review.
Oscarsson J; Hurt-Camejo E
Lipids Health Dis; 2017 Aug; 16(1):149. PubMed ID: 28797250
[TBL] [Abstract][Full Text] [Related]
17. Controversies in the Use of Omega-3 Fatty Acids to Prevent Atherosclerosis.
Quispe R; Alfaddagh A; Kazzi B; Zghyer F; Marvel FA; Blumenthal RS; Sharma G; Martin SS
Curr Atheroscler Rep; 2022 Jul; 24(7):571-581. PubMed ID: 35499805
[TBL] [Abstract][Full Text] [Related]
18. Do patients benefit from omega-3 fatty acids?
Sherratt SCR; Mason RP; Libby P; Steg PG; Bhatt DL
Cardiovasc Res; 2024 Feb; 119(18):2884-2901. PubMed ID: 38252923
[TBL] [Abstract][Full Text] [Related]
19. A biological rationale for the disparate effects of omega-3 fatty acids on cardiovascular disease outcomes.
Sherratt SCR; Libby P; Bhatt DL; Mason RP
Prostaglandins Leukot Essent Fatty Acids; 2022 Jul; 182():102450. PubMed ID: 35690002
[TBL] [Abstract][Full Text] [Related]
20. Eicosapentaenoic acid vs. docosahexaenoic acid for the prevention of cardiovascular disease.
Sweeney TE; Gaine SP; Michos ED
Curr Opin Endocrinol Diabetes Obes; 2023 Apr; 30(2):87-93. PubMed ID: 36562280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
